Between 2017 and 2021, the healthcare sector received $28.9 billion in private AI investment worldwide. This was the largest amount of funding across all industries during that time. This shows that many people believe AI can improve healthcare, diagnoses, and patient results.
In the U.S., the Food and Drug Administration (FDA) controls AI software systems as medical devices using a process called 510(k) clearance. However, this FDA process was created in 1976, when medical devices were mostly physical tools, not software that uses large amounts of data and updates often.
Currently, nearly 900 medical devices that use AI or machine learning have FDA clearance under this system. Most are Class II devices, which means they are considered moderate risk. But this broad category may not fit all AI tools well, since different AI devices can have different risk levels in medical use.
The current FDA rules and other health laws like HIPAA were made before AI was common in medicine. They were designed for traditional medical devices and paper records, which are very different from AI software that learns from data and updates continuously.
One problem is that many AI medical devices do several tasks. Because of this, getting separate FDA approval for each part is hard and often not practical. This slows down the use and development of AI tools in healthcare.
Another problem is the lack of clear information about how AI models work, their risks, and how well they perform in real medical settings. Doctors and health staff often don’t have enough details to fully trust AI tools, which makes them hesitant to use them with patients.
There is also debate about how much human oversight is needed when using AI in medicine. Some people say humans must always be involved to keep safety and responsibility. Others believe AI should work fully on its own to reduce work and increase speed. Combining both ideas with doctors supervising AI is seen as a good middle ground.
In May 2024, a group of 55 experts from different fields met at the Stanford Institute for Human-Centered AI. They talked about gaps in current AI regulations. One major idea was to create a more detailed system for classifying the risks of AI medical devices.
Instead of broad groups like Class II (moderate risk), they suggested adding smaller categories based on the real clinical impact of each AI function. For example, AI tools that help with low-risk diagnostics would be regulated differently than those making important decisions that affect patient health.
This approach would help the FDA and other agencies use their resources better and create clearer safety rules for healthcare providers.
To fix problems with the old approval system from 1976, the experts suggested public-private partnerships. These would improve how information about device performance and safety is shared between AI makers, regulators, and healthcare groups.
Another idea was to increase transparency about AI designs and risks by using “model cards.” These cards would give detailed information about how AI algorithms work, their limits, and the data they use. This would help medical administrators, IT teams, and doctors better understand the tools.
It was also suggested to improve post-market surveillance and real-world performance checks. This means watching AI systems after approval to make sure they stay safe. This ongoing monitoring can quickly spot problems when AI tools are used in everyday healthcare and protect patients.
One important point is about patient knowledge and involvement. Patients should be told when AI is part of their care, like during automated messages or mental health chatbots. But usually, hospitals and clinics decide when and how to share this information.
Ethical concerns include fairness, data protection, avoiding harmful biases, and making sure AI does not increase health differences among people. Patients’ views are important in making policies that build trust and provide fair access to AI healthcare.
Besides diagnosis and clinical decisions, AI is being used more to automate office tasks in medical clinics. This includes answering phone calls, scheduling appointments, and patient communication. Companies like Simbo AI offer AI tools for phone automation designed for healthcare providers.
By automating routine work such as answering calls and confirming appointments, AI can reduce the workload on staff. This lets medical offices spend more time and resources on patient care instead of paperwork.
AI automation also works well with clinical systems by helping write patient messages and take notes using smart technology. These tools help make workflows smoother, lower errors from manual work, and improve the efficiency of medical clinics.
For IT managers and medical practice owners in the U.S., using AI for workflow automation can lower costs, improve patient access, and meet legal rules, as long as the AI services are clear and protect data.
The healthcare field faces a complicated system of rules as it adjusts to AI’s growing role. Some experts say the current system is like “driving a 1976 Chevy Impala on 2024 roads,” meaning it is out of date and needs updating fast.
Groups like the Stanford HAI Healthcare AI Policy Steering Committee bring together different people to keep working on research and new rules. Their focus is on balancing new ideas and safety while making healthcare fair through updated and flexible regulations.
For medical practice administrators, clinic owners, and IT managers in the U.S., knowing about these changes and preparing for new rules will be important. Keeping up with new AI approvals, transparency tools, and automation can help healthcare organizations use AI safely and follow the law.
Key ethical concerns include patient safety, harmful biases, data security, transparency of AI algorithms, accountability for clinical decisions, and ensuring equitable access to AI technologies without exacerbating health disparities.
Current regulations like the FDA’s device clearance process and HIPAA were designed for physical devices and analog data, not complex, evolving AI software that relies on vast training data and continuous updates, creating gaps in effective oversight and safety assurance.
Streamlining market approval through public-private partnerships, enhancing information sharing on test data and device performance, and introducing finer risk categories tailored to the potential clinical impact of each AI function are proposed strategies.
Opinions differ; some advocate for human-in-the-loop to maintain safety and reliability, while others argue full autonomy may reduce administrative burden and improve efficiency. Hybrid models with physician oversight and quality checks are seen as promising compromises.
Developers should share detailed information about AI model design, functionality, risks, and performance—potentially through ‘model cards’—to enable informed decisions about AI adoption and safe clinical use.
In some cases, especially patient-facing interactions or automated communications, patients should be informed about AI involvement to ensure trust and understanding, while clinical decisions may be delegated to healthcare professionals’ discretion.
There is a lack of clear regulatory status for these tools, which might deliver misleading or harmful advice without medical oversight. Determining whether to regulate them as medical devices or healthcare professionals remains contentious.
Engaging patients throughout AI design, deployment, and regulation helps ensure tools meet diverse needs, build trust, and address or avoid worsening health disparities within varied populations.
They provide ongoing monitoring of AI tool performance in real-world settings, allowing timely detection of safety issues and facilitating transparency between developers and healthcare providers to uphold clinical safety standards.
Multidisciplinary research, multistakeholder dialogue, updated and flexible regulatory frameworks, and patient-inclusive policies are essential to balance innovation with safety, fairness, and equitable healthcare delivery through AI technologies.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
